A case of bullous pemphigoid associated with the administration of ipragliflozin, a sodium-glucose cotransporter 2 inhibitor

Kayoko Ikehara, Hiroshi Uchino, Yuki Kakumae, Nahoko Miyashita, Hiroshi Yoshino, Masahiko Miyagi, Naoki Kumashiro, Takahisa Hirose

研究成果: Article査読

抄録

We herein describe the case of an 83-year-old man with type 2 diabetes treated with the sodium glucose transporter-2 (SGLT2) inhibitor Ipragliflozin who developed bullous pemphigoid (BP). Five months after the administration of Ipragliflozin, he began to show pruritus multiforme, and blisters spread over the trunk of the body to the forearm. Based on the findings of a clinical examination and the presence of autoantibodies to BP antigen, BP 180, and consequently positive interferon gamma production to lymphocyte stimulation by Ipragliflozin, we confirmed the diagnosis as BP. Systemic glucocorticoid administration improved the symptoms and all skin lesions. The development of BP has not been reported in a patient receiving SGLT2 inhibitors. We herein report the first case of BP that developed following the administration of an SGLT2 inhibitor and discuss the association of BP with the administration of drugs for diabetes.

本文言語English
ページ(範囲)59-63
ページ数5
ジャーナルJournal of the Japan Diabetes Society
61
2
DOI
出版ステータスPublished - 2018
外部発表はい

All Science Journal Classification (ASJC) codes

  • 内科学
  • 内分泌学、糖尿病および代謝内科学
  • 内分泌学

フィンガープリント

「A case of bullous pemphigoid associated with the administration of ipragliflozin, a sodium-glucose cotransporter 2 inhibitor」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル